8 Best Up and Coming Penny Stocks to Buy Now
The article lists eight “up and coming” penny stocks, selected via screeners for IPOs in the past five years and recent developments. It highlights NeOnc Technologies (NTHI) at $4.64, with Alliance Global and Maxim initiating Buy ratings and $13/$20 targets, and AirJoule (AIRJ) at $4.49, after a Q1 update and Seaport Research’s $7 Buy target.
How this was made
The 30-second read
Why it matters
For NTHI, the incremental trading driver is sell-side initiation with targets tied to its intranasal small-molecule brain-cancer approach and NEO delivery platform. For AIRJ, the incremental driver is reported progress on AirJoule Prime build completion and AirJoule Core design lock, plus a roadmap spanning water generation and dehumidification variants.
Market read
This is sentiment-supportive for the two highlighted tickers (coverage initiations and execution milestones), but it is not a fundamental earnings/clinical outcome update.
What to watch
No discussion of burn rate, balance-sheet runway, trial timelines, regulatory risk, or customer adoption metrics—key drivers for both names’ risk/reward.
Background
The piece is a general “best up-and-coming penny stocks” roundup, using screeners for recent IPOs and recent “noteworthy developments,” then highlighting two specific companies with analyst initiations or operational updates.
Ticker impact
NeOnc received two fresh analyst coverage initiations (May 19 and May 18) with Buy ratings and $13/$20 targets for its brain-cancer pipeline.
Mild-to-moderate upside bias for momentum traders; follow-through depends on subsequent clinical/data catalysts.
The article’s actionable catalyst is analyst initiation/targets, not new clinical results; impact is likely sentiment-driven rather than fundamental re-rating.
AirJoule reported Q1 progress: full-scale build of AirJoule Prime at Newark and AirJoule Core moved to locked design stage.
Potential short-term bid as traders price execution progress; magnitude likely capped without revenue/contract confirmation.
The article provides specific development milestones and a new roadmap, but no disclosed commercial traction or financial datapoint.
Market effects
Reinforces retail interest and speculative flows into early-stage biotech (brain cancer delivery) and climate/water tech (atmospheric water generation).
Primarily US-listed small-cap sentiment; no explicit regional macro linkage.
Themes (neuro-oncology delivery and water scarcity tech) are globally relevant but the article is company-specific, not a global policy shock.
Counterpoint
Analyst price targets and design-stage milestones may not translate into near-term cash flows; penny-stock volatility can reverse quickly on dilution/financing risk not discussed here.
Key entities
- companyNeOnc Technologies Holdings
Clinical-stage biopharma developing intranasally delivered small-molecule therapies for aggressive brain cancers; NEO platform targets blood-brain barrier delivery.
- companyAirJoule Technologies
Atmospheric renewable energy and water harvesting company; reports AirJoule Prime build completion and AirJoule Core design lock via its platform.
